Zusammenfassung
Zu den Manifestationen der progressiven systemischen Sklerodermie (PSS) im Bereich
der Hände zählen das Raynaud-Phänomen, die Calcinosis cutis, die Sklerodaktylie und
Teleangiektasien. In fortgeschrittenen Stadien der Erkrankung kann es zu dermatogenen
oder arthrogenen Kontrakturen, Akroosteolysen und Fingerkuppennekrosen bis hin zu
ausgedehnten digitalen Ulzerationen kommen. Diese oft schnell progredienten und deutlich
dolenten Befunde führen neben Funktionseinschränkungen zu einer erheblichen Stigmatisierung
und resultieren unbehandelt häufig in Verstümmelungen. Nur durch ein interdisziplinäres
Management unter Mitwirkung von Handchirurgen, Rheumatologen und Physiotherapeuten
kann eine optimale Therapie der Manifestationen der PSS im Bereich der Hände gelingen.
Medikamentöse und physikalische Maßnahmen sollten bekannt sein und vor chirurgischen
Interventionen ausgeschöpft beziehungsweise begleitend eingeleitet werden. Die chirurgische
Therapie beinhaltet neben der Infekttherapie vor allem die Exzision der Kalkherde,
Arthrodesen, insbesondere der proximalen Interphalangealgelenke, und die Sympathektomie.
Die Amputation nekrotischer Finger bleibt Teil des Therapiekonzeptes, wobei bei rechtzeitiger
suffizienter Therapie eine Amputation vermieden und meist eine Funktionsverbesserung
und Symptomlinderung erreicht werden kann. Unter den nicht-operativen Maßnahmen haben
sich vor allem Verhaltensschulungen, der Einsatz von Kalziumantagonisten, Prostazyklinderivaten
und topischen Nitraten sowie Plexusanästhesien und Stellatum-Blockaden bewährt. Zu
den neuen medikamentösen Therapieoptionen zählen Endothelin-Rezeptor-Antagonisten
für die Prävention neuer digitaler Ulzerationen und Phosphodiesterase-V-Hemmer für
die Behandlung des Raynaud-Phänomens und die Abheilung akraler Ulzerationen. Am Beispiel
eigener Patienten stellen wir multimodale Therapiekonzepte akraler Manifestationen
der PSS vor.
Abstract
Clinical manifestations of scleroderma at the hand include Raynaud's phenomenon, calcinosis
cutis, sclerodactylia and teleangiectasia. With the progression of the disease, cutaneous
and joint contractions, acro-osteolysis, necrosis of the finger tips, and even extensive
digital ulceration are likely to occur. These painful and often rapidly advancing
lesions cause loss of function and disfigurement and, untreated, often lead to mutilation
of the affected hand. Only an interdisciplinary management including the hand surgeon,
the rheumatologist, and the physiotherapist can guarantee optimal treatment. Drug
therapy should be included as well as physical therapy. Both should be made use of
before and accompanying surgical treatment. Surgical therapy consists of treatment
of the infections, excision of calcinosis, arthrodesis, in particular of the proximal
interphalangeal joints, and sympathectomy. Amputation remains a final option, whereas
with timely and sufficient treatment, amputations can be avoided and an improvement
of function and an alleviation of the symptoms can be achieved. Among the non-operative
treatment options, behavioural training, calcium antagonists, prostacyclin derivatives,
topical nitrates as well as plexus anesthesia and stellatum blocks have proved to
be effective. Recent drug therapies include endothelin-receptor antagonists for the
prevention of digital ulceration and phosphodiesterase-V antagonists in treatment
of Raynaud's phenomenon and induction of ulcer healing. With reference to several
cases seen at our institution, we propose an interdisciplinary treatment concept for
acral manifestations of scleroderma.
Schlüsselwörter
Sklerodermie - multimodales Therapiekonzept - interdisziplinäres Management - Handchirurgie
Key words
scleroderma - multimodal therapy - interdisciplinary management - hand surgery
Literatur
1
Balogh B, Mayer W, Vesely M, Mayer S, Partsch H, Piza-Katzer H.
Adventitial stripping of the radial and ulnar arteries in Raynaud's disease.
J Hand Surg [Am].
2002;
27
1073-1080
2
Coffman J D, Cohen R A.
Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human
digits.
Eur J Clin Invest.
1988;
18
309-313
3
Coffman J D, Rasmussen H M.
Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon.
Circulation.
1985;
72
466-470
4
Denton C P, Howell K, Stratton R J, Black C M.
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A
pilot study.
Clin Exp Rheumatol.
2000;
18
499-502
5
Dziadzio M, Denton C P, Smith R, Howell K, Blann A, Bowers E, Black C M.
Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical
findings in a fifteen-week, randomized, parallel-group, controlled trial.
Arthritis Rheum.
1999;
42
2646-2655
6
Flatt A E.
Digital artery sympathectomy.
J Hand Surg.
1980;
5
550-556
7
Flavahan N A, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener C M, Spence R J, Wigley F M.
Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.
Arthritis Rheum.
2000;
43
1886-1890
8
Freedman R R, Girgis R, Mayes M D.
Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.
J Rheumatol.
1999;
26
2386-2388
9
Fulcher S M, Koman L A, Smith B P, Holden M, Smith T L.
The effect of transdermal nicotine on digital perfusion in reformed habitual smokers.
J Hand Surg [Am].
1998;
23
792-799
10
Goerz G, Hammer G, Wirth G, Hornstein O P, Keller G J, Altmeyer P, Holzmann H, Meigel W,
Mensing H, Braun-Falco O. et al. .
Clinical aspects of progressive systemic scleroderma (PSS). Multicenter studies of
194 patients.
Hautarzt.
1986;
37
320-324
11
Hummers L K, Wigley F M.
Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
Rheum Dis Clin North Am.
2003;
29
293-313
12
Jones N F.
Acute and chronic ischemia of the hand: Pathophysiology, treatment, and prognosis.
J Hand Surg [Am].
1991;
16
1074-1083
13
Kahaleh M B, Fan P S.
Mechanism of serum-mediated endothelial injury in scleroderma: Identification of a
granular enzyme in scleroderma skin and sera.
Clin Immunol Immunopathol.
1997;
83
32-40
14
Korn J H, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P,
Molitor J, Seibold J R, Hsu V, Guillevin L, Chatterjee S, Peter H H, Coppock J, Herrick A,
Merkel P A, Simms R, Denton C P, Furst D, Nguyen N, Gaitonde M, Black C.
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral
endothelin receptor antagonist.
Arthritis Rheum.
2004;
50
3985-3993
15
Lau C S, McLaren M, Saniabadi A, Belch J J.
Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with
or without systemic sclerosis.
Scand J Rheumatol.
1993;
22
97-101
16
LeRoy E C, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr T A, Rowell N,
Wollheim F.
Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis.
J Rheumatol.
1988;
15
202-205
17
Masi A T, Rodnan G P, Medsger T A, Altman R D, D'Angelo W A, Fries J F, LeRoy E C,
Kirsner A B, MacKenzie A H, McShane D J, Myers A R, Sharp G C.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee
for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic
Criteria Committee.
Arthritis Rheum.
1980;
23
581-590
18
Melone Jr C P, McLoughlin J C, Beldner S.
Surgical management of the hand in scleroderma.
Curr Opin Rheumatol.
1999;
11
514-520
19
Nalebuff E A.
Surgery in patients with systemic sclerosis of the hand.
Clin Orthop.
1999;
366
91-97
20
Omote K, Kawamata M, Namiki A.
Adverse effects of stellate ganglion block on Raynaud's phenomenon associated with
progressive systemic sclerosis.
Anesth Analg.
1993;
77
1057-1060
21
Riemekasten G.
Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome
and acral ulcerations.
Z Rheumatol.
2005;
64
90-92
22
Riemekasten G, Jepsen H, Burmester G R, Hiepe F.
Iloprostgabe über 21 Tage als wirksame Therapie bei der progressiven Sklerodermie
- Fallbeschreibung und Literaturübersicht.
Z Rheumatol.
1998;
57
118-124
23
Rodnan G P, Myerowitz R L, Justh G O.
Morphologic changes in the digital arteries of patients with progressive systemic
sclerosis (scleroderma) and Raynaud phenomenon.
Medicine (Baltimore).
1980;
59
393-408
24
Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E.
Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient
with scleroderma-associated lung fibrosis and the raynaud phenomenon.
Ann Intern Med.
2003;
139
871-873
25
Thibierge G, Weissenbach R-J.
Concrétions calcaires sous-cutanées et sclerodermie.
Ann Derm Syphil.
1911;
2
129-155
26
Thompson A E, Shea B, Welch V, Fenlon D, Pope J E.
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Arthritis Rheum.
2001;
44
1841-1847
27
Watson H R, Robb R, Belcher G, Belch J J.
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary
to systemic sclerosis.
J Rheumatol.
1992;
19
1407-1414
28
Wigley F M, Wise R A, Miller R, Needleman B W, Spence R J.
Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic
sclerosis.
Arthritis Rheum.
1992;
35
688-693
29
Wilgis E F.
Local muscle flaps in the hand. Anatomy as related to reconstructive surgery.
Bull Hosp Jt Dis Orthop Inst.
1984;
44
552-557
30
Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L.
Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous
iloprost in systemic sclerosis.
Acta Derm Venereol.
1996;
76
236-238
Dr. med. Adrien Daigeler
Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte Handchirurgiezentrum Berufsgenossenschaftliche Kliniken Bergmannsheil
Bürkle-de-la-Camp-Platz 1
44789 Bochum
Email: adrien.daigeler@rub.de